Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2980172 | 0.79 | USP2 (0.39) | USP2SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL1978663 | 0.79 | USP2 (0.39) | USP2SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL2904445 | 0.79 | USP2 (0.39) | USP2SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL1982415 | 0.78 | USP2 (0.38) | USP2SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL1980306 | 0.78 | USP2 (0.38) | USP2SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL1982417 | 0.78 | USP2 (0.38) | USP2SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL1979775 | 0.78 | USP2 (0.38) | USP2SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL1980305 | 0.78 | USP2 (0.38) | USP2SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL12598645 | 0.78 | USP2 (0.38) | USP2SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL17190805 | 0.76 | USP2 (0.42) | USP2SMN1; SMN2NR1H2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340564-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250101034-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2025-03-27 | — | — | US | disclosed |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| EP-4426704-A1 | CONDENSED PYRIDAZINE AMINE DERIVATIVES TREATING SCA3 | Skyhawk Therapeutics, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2023081858-A1 | CONDENSED-PYRAZINE AMINE DERIVATIVES FOR TREATING SCA3 | SKYHAWK THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081857-A1 | CONDENSED PYRIDAZINE AMINE DERIVATIVES TREATING SCA3 | SKYHAWK THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081857-A1 | CONDENSED PYRIDAZINE AMINE DERIVATIVES TREATING SCA3 | SKYHAWK THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230039309-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-02-09 | — | — | US | disclosed |
| US-11208415-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2021-12-28 | — | — | US | disclosed |
| EP-3122353-B1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | UNIV VANDERBILT (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200140447-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2020-05-07 | — | — | US | disclosed |
| US-20170174689-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2017-06-22 | — | — | US | disclosed |
| EP-3122353-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | Vanderbilt University (US) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015148854-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140447-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL3 | USP2 451/4885SMN1; SMN2 2394/4885NR1H2 2190/4885 |
| US-20250101034-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | RBM17, SNRPE, SNRPA1 | USP2 2869/4885SMN1; SMN2 80/4885NR1H2 921/4885 |
| US-20230039309-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL3 | USP2 451/4885SMN1; SMN2 2394/4885NR1H2 2190/4885 |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL3 | USP2 451/4885SMN1; SMN2 2394/4885NR1H2 2190/4885 |
| US-20250340564-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | RBM17, SNRPE, SNRPA1 | USP2 2869/4885SMN1; SMN2 80/4885NR1H2 921/4885 |
| US-20170174689-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL3 | USP2 451/4885SMN1; SMN2 2394/4885NR1H2 2190/4885 |
| US-11208415-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL3 | USP2 451/4885SMN1; SMN2 2394/4885NR1H2 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.